Upexi beats EPS consensus by $0.91; revenue misses by $3.77m

Upexi reported $0.68 in earnings per share on Tuesday, $0.91 above the consensus figure listed as $(0.23).

The per-share surprise came with a much weaker revenue result: $0.43 million against $4.20 million expected, a $3.77 million gap, or roughly 90%. The source did not supply an accounting bridge for the EPS comparison or explain the divergence between earnings per share and sales, so the beat should not stand alone.

What did the quarter show?

• Quarterly EPS: $0.68, versus a $(0.23) consensus, a $0.91 difference.
• Revenue: $0.43 million, versus $4.20 million expected, a $3.77 million shortfall.
• Net margin: -984.34%.
• Return on equity: -157.49%.

FiscalAI supplied the estimates. The reported net margin and return on equity were both negative, indicating losses relative to revenue and equity. The excerpt gives no cash flow, debt, working-capital or prior-quarter comparisons, and it does not reconcile the positive quarterly EPS reading with those margins.

Takeaway: The per-share beat did not repair the revenue gap.

How did the shares react?

UPXI fell $0.04 on Tuesday to $0.62, a 6.2% decline. Trading volume reached 995,578 shares, compared with an average of 3,530,690, putting session volume at about 28% of average. The source identified no catalyst and offered no explanation for the lighter volume, so it provides little basis for judging the depth of the move.

At $0.62, the shares traded below the $1.00 50-day moving average and the $1.04 200-day moving average. The one-year range ran from $0.54 to $3.65, while market capitalization stood at $54.94 million.

The report also listed a P/E ratio of -0.15 and a beta of -0.28. The negative P/E cannot be assessed from the excerpt alone because the source did not provide trailing earnings or the accounting basis. The figures describe the quoted market data; they do not establish a valuation conclusion.

Takeaway: The market data show no reward for the EPS beat and leave the operating gap unresolved.

What do the analyst calls show?

• Friday, September 4: Weiss Ratings reiterated a “sell (e+)” rating.
• Friday, September 18: Cantor Fitzgerald restated an “overweight” rating and set a $2.00 target price.
• Sunday, September 20: Wall Street Zen cut the rating from “hold” to “sell.”

The disclosed calls did not form a single direction. One research analyst rated UPXI Buy and one rated it Sell. MarketBeat listed the present consensus as “Hold” with a $5.00 consensus target.

That target stood $4.38 above Tuesday’s $0.62 quoted price and more than eight times the traded price. The source did not publish valuation assumptions, analyst methodology or other inputs, so readers cannot test the spread from the available data.

Takeaway: Analyst opinions remain split, and the stated target is not a substitute for operating evidence.

What does Upexi actually sell?

Upexi, Inc. (NASDAQ: UPXI) describes itself as a consumer products company that develops, acquires and manages brands sold through e-commerce and other retail channels. Its portfolio has included wellness, beauty, pet care, household goods and consumer accessories.

The multichannel model includes third-party online marketplaces, including Amazon, direct-to-consumer websites and selected retail distribution. Upexi’s activities generally cover product development, brand management, supply-chain coordination, marketing and fulfillment.

The description does not disclose current revenue by category or channel, inventory, supplier concentration, cash generation or forward guidance. The source therefore cannot show which part of the model produced the $0.43 million quarterly revenue figure or whether management expects the $4.20 million consensus gap to narrow.

Takeaway: The business model is broad, but channel economics and forward guidance remain absent.